newsfilter
← Latest News
Business Wire·

Exscientia Business Update for Second Quarter and First Half 2024

Entered into definitive agreement to combine with Recursion to create a global technology-enabled drug discovery leader with end-to-end capabilities Acquired full rights to GTAEXS617 (CDK7 inhibitor), with initial